6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
about
High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomasDiagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelinesUpdate on therapeutic options in Waldenström macroglobulinemiaMYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemiaClinical factors associated with response or survival after chemotherapy in patients with Waldenström macroglobulinemia in Korea.International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.Waldenstrom macroglobulinemiaDevelopment and characterization of a novel human Waldenström macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenström Macroglobulinemia 1.Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia.Waldenström macroglobulinaemia and IgM monoclonal gammopathy of undetermined significance: emerging understanding of a potential precursor condition.Candidate genes of Waldenström's macroglobulinemia: current evidence and research.Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma.Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation.Molecular pathogenesis of Waldenstrom's macroglobulinemia.Genetic factors and pathogenesis of Waldenström's macroglobulinemia.Waldenström macroglobulinemia: from biology to treatment.Waldenstrom Macroglobulinemia: Genomic Aberrations and Treatment.An unusual case of Waldenstrom's macroglobulinemia presented with nasopharyngeal involvement.From Waldenström's macroglobulinemia to aggressive diffuse large B-cell lymphoma: a whole-exome analysis of abnormalities leading to transformation.Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia.IgM multiple myeloma: disease definition, prognosis, and differentiation from Waldenstrom's macroglobulinemia.Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.Advances in the understanding of IgM monoclonal gammopathy of undetermined significance.Del17p does not always significantly influence the survival of B-cell chronic lymphoproliferative disorders.Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.Analysis of 6q deletion in Waldenstrom macroglobulinemia.6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosisGene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion
P2860
Q28241121-683E9E6D-F434-48B5-837A-1518334D367AQ28290236-AED019CB-9D20-4162-B96D-2FFB4248169BQ28304195-137183E7-BABC-4495-80C0-B885D5D4D2D5Q33660823-2A16E59A-5E0D-494C-AAE8-1D918FC86C08Q33786873-8B4630E9-C10B-4224-A8D0-606EB3D48DBBQ34241661-6A516D56-D56B-4EC2-850D-2D2DD6D90F1AQ35097328-0EC0E557-15ED-49D2-A430-0496307460BEQ35524194-8AC3A54E-E6E5-41FF-B5D6-02E68F7A00A3Q36862542-93B5B3E6-342F-42BB-A73F-0DB2E0A6CB1BQ37004853-015BF0C9-C8BB-45AA-B24D-35B0F2AF1A7FQ37074275-E55F04E9-36FC-426F-9C92-0A0848FD3D38Q37621361-C9173751-4257-46F4-80ED-B9881FCFD7E8Q37901235-41592C8E-0C4B-4B31-92A4-5CDACE259B88Q38024773-2AAD9DFF-37F1-4707-962F-775C548628F4Q38125430-788A26C3-EEFD-4F52-99D3-400C1AE93AF1Q38176969-5F546EC2-4F29-4EDE-81E2-AA434BEA7EB2Q38970612-BA73A013-BC0B-45BB-B5C1-B3E40D5B8644Q40230100-ECC40649-F8AC-4F22-81E1-1CBECA166E84Q41177165-7EF9FF68-3B60-47D0-B4D8-E3781E7325B9Q42127664-E849FF44-C157-455F-8242-2D267A4051DEQ42543925-6DE502D2-640A-4244-AB58-A63C1073AAFFQ44335401-2B339FF4-3295-4747-B26C-F648BC82C4E8Q48109341-FF5AC147-077C-4C7E-92C0-D09E94D34263Q48505196-A32CECA7-EE24-45A9-B290-49DC00D8F8F5Q51199274-FEC9C946-BF8F-458D-8DCF-F29944A37F94Q53966603-BE1FAF45-7EDF-40F9-8401-430E1FA39842Q58050808-2E99B1BB-E193-4640-83F6-DA7034C508C2Q58583276-CDC284B9-0AE4-486E-845C-22FC28C42FB0
P2860
6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
6q deletion discriminates Wald ...... y of undetermined significance
@ast
6q deletion discriminates Wald ...... y of undetermined significance
@en
6q deletion discriminates Wald ...... y of undetermined significance
@nl
type
label
6q deletion discriminates Wald ...... y of undetermined significance
@ast
6q deletion discriminates Wald ...... y of undetermined significance
@en
6q deletion discriminates Wald ...... y of undetermined significance
@nl
prefLabel
6q deletion discriminates Wald ...... y of undetermined significance
@ast
6q deletion discriminates Wald ...... y of undetermined significance
@en
6q deletion discriminates Wald ...... y of undetermined significance
@nl
P2093
P50
P1476
6q deletion discriminates Wald ...... y of undetermined significance
@en
P2093
Gregory J Ahmann
Irene Ghobrial
Philip R Greipp
Rafael Fonseca
Roelandt F J Schop
Ruifang Xu
Scott A Van Wier
P356
10.1016/J.CANCERGENCYTO.2006.04.009
P407
P577
2006-09-01T00:00:00Z